Join

Compare · GLMD vs NVO

GLMD vs NVO

Side-by-side comparison of Galmed Pharmaceuticals Ltd. (GLMD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both GLMD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $222.81B, about 53117.4x GLMD ($4.2M).
  • Over the past year, GLMD is down 70.3% and NVO is down 22.5% - NVO leads by 47.7 points.
  • NVO has been more active in the news (4 items in the past 4 weeks vs 3 for GLMD).
  • NVO has more recent analyst coverage (25 ratings vs 0 for GLMD).
PerformanceGLMD-70.25%NVO-22.53%
2025-07-21+0.00%2026-07-17
MetricGLMDNVO
Company
Galmed Pharmaceuticals Ltd.
Novo Nordisk A/S
Price
$0.54-2.58%
$50.31-2.25%
Market cap
$4.2M
$222.81B
1M return
-10.75%
+15.47%
1Y return
-70.25%
-22.53%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2014
News (4w)
3
4
Recent ratings
0
25
GLMD

Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.

NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Latest GLMD

Latest NVO